Evaluation of Safety, efficacy, and QOL with Glecaprevir and Pibrentasvir therapy in Dialysis Patients Infected with Hepatitis C Virus
Latest Information Update: 06 Dec 2017
Price :
$35 *
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 06 Dec 2017 New trial record